Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

11.8%

2 terminated/withdrawn out of 17 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

41%

7 trials in Phase 3/4

Results Transparency

57%

8 of 14 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 3

6(46.2%)

Phase 2

5(38.5%)

Phase 4

1(7.7%)

Phase 1

1(7.7%)

13Total

Phase 3(6)

Phase 2(5)

Phase 4(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT05255900Completed

Effects of Metyrapone in Patients With Hypercortisolism

Role: collaborator

NCT00290251Phase 2Completed

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

Role: collaborator

NCT03208985Phase 3Completed

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

Role: lead

NCT04872920Unknown

Observational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole.

Role: lead

NCT04112095Phase 3Completed

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

Role: lead

NCT00551616Phase 3Completed

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

Role: lead

NCT03559010Phase 3Terminated

A Study of Oral Contraception Under Simulated OTC Conditions

Role: lead

NCT00411684Phase 3Completed

Safety and Efficacy of CDB-2914 for Emergency Contraception

Role: lead

NCT03585712Phase 2Completed

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

Role: lead

NCT00721201Phase 1Completed

Glucocorticoid Receptor Antagonism in Subclinical Cushings

Role: collaborator

NCT02297945Phase 3Completed

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

Role: lead

NCT01569737Completed

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

Role: lead

NCT00422201Phase 2Terminated

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

Role: lead

NCT01569113Phase 4Completed

Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.

Role: lead

NCT01107106Completed

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

Role: lead

NCT01107093Phase 2Completed

Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge

Role: lead

NCT00456924Phase 2Completed

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914

Role: lead

All 17 trials loaded